CRISPR/Cas9-Multiplexed Editing of Chinese Hamster Ovary B4Gal-T1, 2, 3, and 4 Tailors N-Glycan Profiles of Therapeutics and Secreted Host Cell Proteins.

In production of recombinant proteins for biopharmaceuticals, N-glycosylation is often important for protein efficacy and patient safety. IgG with agalactosylated (G0)-N-glycans can improve the activation of the lectin-binding complement system and be advantageous in the therapy of lupus and virus diseases. In this study, the authors aimed to engineer CHO-S cells for the production of proteins with G0-N-glycans by targeting B4Gal-T isoform genes with CRISPR/Cas9. Indel mutations in genes encoding B4Gal-T1, -T2, and -T3 with and without a disrupted B4Gal-T4 sequence resulted in only ≈1% galactosylated N-glycans on total secreted proteins of 3-4 clones per genotype. The authors revealed that B4Gal-T4 is not active in N-glycan galactosylation in CHO-S cells. In the triple-KO clones, transiently expressed erythropoietin (EPO) and rituximab harbored only ≈6% and ≈3% galactosylated N-glycans, respectively. However, simultaneous disruption of B4Gal-T1 and -T3 may decrease cell growth. Altogether, the authors present the advantage of analyzing total secreted protein N-glycans after disrupting galactosyltransferases, followed by expressing recombinant proteins in selected clones with desired N-glycan profiles at a later stage. Furthermore, the authors provide a cell platform that prevalently glycosylates proteins with G0-N-glycans to further study the impact of agalactosylation on different in vitro and in vivo functions of recombinant proteins.

[1]  Vaibhav Jadhav,et al.  Enhanced Genome Editing Tools For Multi-Gene Deletion Knock-Out Approaches Using Paired CRISPR sgRNAs in CHO Cells. , 2018, Biotechnology journal.

[2]  F. Leisch,et al.  Karyotype variation of CHO host cell lines over time in culture characterized by chromosome counting and chromosome painting , 2018, Biotechnology and bioengineering.

[3]  M. Parr,et al.  Comparability study of Rituximab originator and follow‐on biopharmaceutical , 2017, Journal of pharmaceutical and biomedical analysis.

[4]  G. Alter,et al.  The Immunoregulatory Roles of Antibody Glycosylation. , 2017, Trends in immunology.

[5]  B. Snedecor,et al.  FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality , 2017, Biotechnology and bioengineering.

[6]  V. Sandig,et al.  Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans , 2016, Scientific Reports.

[7]  Hui Zhang,et al.  Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N‐glycan branching and sialylation , 2015, Biotechnology and bioengineering.

[8]  Stefan Kol,et al.  One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment. , 2015, Biotechnology journal.

[9]  Claus Kristensen,et al.  Engineered CHO cells for production of diverse, homogeneous glycoproteins , 2015, Nature Biotechnology.

[10]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2014 , 2014, Nature Biotechnology.

[11]  Alex Toftgaard Nielsen,et al.  Accelerating Genome Editing in CHO Cells Using CRISPR Cas9 and CRISPy, a Web-Based Target Finding Tool , 2014, Biotechnology and bioengineering.

[12]  Raymond A. Dwek,et al.  Emerging Principles for the Therapeutic Exploitation of Glycosylation , 2014, Science.

[13]  Edward J. O'Brien,et al.  Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome , 2013, Nature Biotechnology.

[14]  C. Bailey-Kellogg,et al.  Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. , 2013, The Journal of clinical investigation.

[15]  Jörg Knäblein,et al.  Modern biopharmaceuticals : recent success stories , 2013 .

[16]  Peter G. Slade,et al.  Identifying the CHO secretome using mucin-type O-linked glycosylation and click-chemistry. , 2012, Journal of proteome research.

[17]  Jianwei Zhu,et al.  Mammalian cell protein expression for biopharmaceutical production. , 2012, Biotechnology advances.

[18]  L. Rönnblom,et al.  IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: a possible new treatment? , 2012, Arthritis and rheumatism.

[19]  P. Soler-Palacín,et al.  Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion , 2012, Orphanet Journal of Rare Diseases.

[20]  Marcella Yu,et al.  Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.

[21]  Kelvin H. Lee,et al.  The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line , 2011, Nature Biotechnology.

[22]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[23]  Jeffrey C. Miller,et al.  Highly efficient deletion of FUT8 in CHO cell lines using zinc‐finger nucleases yields cells that produce completely nonfucosylated antibodies , 2010, Biotechnology and bioengineering.

[24]  Naoko Yamane-Ohnuki,et al.  Production of therapeutic antibodies with controlled fucosylation , 2009, mAbs.

[25]  J. Ravetch,et al.  Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity , 2007, Proceedings of the National Academy of Sciences.

[26]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[27]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[28]  R. Bayer,et al.  GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. , 2006, Glycobiology.

[29]  S. Iida,et al.  Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa , 2006, Clinical Cancer Research.

[30]  S. Guo,et al.  Galactosylation of N-linked oligosaccharides by human beta-1,4-galactosyltransferases I, II, III, IV, V, and VI expressed in Sf-9 cells. , 2001, Glycobiology.

[31]  B. Ramakrishnan,et al.  Crystal structure of lactose synthase reveals a large conformational change in its catalytic component, the beta1,4-galactosyltransferase-I. , 2001, Journal of molecular biology.

[32]  Pamela Stanley,et al.  Chinese Hamster Ovary (CHO) Cells May Express Six β4-Galactosyltransferases (β4GalTs) , 2001, The Journal of Biological Chemistry.

[33]  H. Clausen,et al.  Identification and characterization of large galactosyltransferase gene families: galactosyltransferases for all functions. , 1999, Biochimica et biophysica acta.

[34]  T. Sato,et al.  Beta-1,4-galactosylation of N-glycans is a complex process. , 1999, Biochimica et biophysica acta.

[35]  E. Bennett,et al.  Cloning and Expression of a Proteoglycan UDP-Galactose:β-Xylose β1,4-Galactosyltransferase I , 1999, The Journal of Biological Chemistry.

[36]  K. Yoshida,et al.  Human Homolog of Caenorhabditis elegans sqv-3 Gene Is Galactosyltransferase I Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of Proteoglycans* , 1999, The Journal of Biological Chemistry.

[37]  D. H. van den Eijnden,et al.  The acceptor substrate specificity of human β4‐galactosyltransferase V indicates its potential function in O‐glycosylation , 1999, FEBS letters.

[38]  O Hindsgaul,et al.  Synthesis of Poly-N-acetyllactosamine in Core 2 Branched O-Glycans , 1998, The Journal of Biological Chemistry.

[39]  S L Morrison,et al.  Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. , 1998, Journal of immunology.

[40]  Y. Iwakura,et al.  Growth retardation and early death of β‐1, 4‐galactosyltransferase knockout mice with augmented proliferation and abnormal differentiation of epithelial cells , 1997, The EMBO journal.

[41]  R. Dwek,et al.  Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein , 1995, Nature Medicine.

[42]  T. Arakawa,et al.  Structural characterization of human erythropoietin. , 1986, The Journal of biological chemistry.

[43]  Kurt Forrer,et al.  Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[44]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[45]  P. Stanley,et al.  Chinese hamster ovary (CHO) cells may express six beta 4-galactosyltransferases (beta 4GalTs). Consequences of the loss of functional beta 4GalT-1, beta 4GalT-6, or both in CHO glycosylation mutants. , 2001, Journal of Biological Chemistry.

[46]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[47]  E. Bennett,et al.  Cloning and expression of a proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I. A seventh member of the human beta4-galactosyltransferase gene family. , 1999, The Journal of biological chemistry.